Stay updated on KarXT for Alzheimer's Psychosis Clinical Trial

Sign up to get notified when there's something new on the KarXT for Alzheimer's Psychosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the KarXT for Alzheimer's Psychosis Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    An NIH-wide notice about the website transition and terminology appears above the ClinicalTrials.gov 403 error page. The footer revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T18:54:50.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The site's footer revision label changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T18:05:51.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the previous study record content and navigation with an access-denied message.
    Difference
    20%
    Check dated 2026-09-22T23:39:11.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The header text changed capitalization from 'Find Contact Information' to 'Find contact information'. The footer revision label updated from 'Revision: v3.6.6' to 'Revision: v3.7.0', indicating a minor version update.
    Difference
    0.0%
    Check dated 2026-09-16T00:08:27.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page's revision metadata was updated from v3.6.5 to v3.6.6.
    Difference
    0.0%
    Check dated 2026-09-01T19:37:41.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The page adds new recruitment sites and investigators (including CHU de Reims and Fondazione Policlinico A Gemelli - Rome; Jean Luc Novella at Site 2501 and Camillo Marra at Site 2303), updates informed consent language and caregiver/contraception requirements, and expands the study plan with time-to-relapse endpoints (up to Week 38) and related safety and outcome measures.
    Difference
    0.6%
    Check dated 2026-08-18T16:15:34.000Z thumbnail image

Stay in the know with updates to KarXT for Alzheimer's Psychosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the KarXT for Alzheimer's Psychosis Clinical Trial page.